SCHEMBL3978022

SCHEMBL3978022

N#CCc1ccc(CC(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.56
CAMK2A Q9UQM7 1/20 0.56
AKR1B1 P15121 1/20 0.54
RXRA P19793 3/20 0.53
RXRG P48443 3/20 0.53
RXRB P28702 2/20 0.53
LMNA P02545 2/20 0.52
GAA P10253 2/20 0.52
TSHR P16473 2/20 0.52
ABCC4 O15439 1/20 0.52
PTGS1 P23219 1/20 0.52
HTT P42858 1/20 0.52
FFAR1 O14842 2/20 0.52
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
POLB P06746 2/20 0.46
NSD2 O96028 1/20 0.46
GRK2 P25098 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylacetic Acid SCHEMBL5322767 0.92 AKR1B1 (0.68) CA2CAMK2AAKR1B1RXRARXRG
SCHEMBL31481194 0.81 CA2 (0.57) CA2LMNAHTTKMT2AMAPT
SCHEMBL11011416 0.81 POLB (0.47) CA2CAMK2ARXRARXRGRXRB
SCHEMBL69614 0.81 CA2 (0.79) CA2CAMK2AAKR1B1LMNAGAA
SCHEMBL25227656 0.80 KMT2A (0.42) CA2CAMK2ARXRARXRGRXRB
SCHEMBL8943904 0.80 CA2 (0.58) CA2CAMK2AAKR1B1LMNAGAA
SCHEMBL11551946 0.79 FFAR1 (0.63) CA2FFAR1
SCHEMBL211305 0.78 ALDH1A1 (0.54) CA2GAATSHRPTGS1KMT2A
SCHEMBL335492 0.78 CTBP2 (0.62) CA2CAMK2AAKR1B1RXRARXRG
SCHEMBL27834238 0.78 CA2 (0.83) CA2CAMK2AAKR1B1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714240-B2 Vinyl autotaxin inhibitor compounds PHARMAKEA, INC. (US) 2017-07-25 US disclosed
US-20160222000-A1 VINYL AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2016-08-04 US disclosed
EP-3046905-A1 VINYL AUTOTAXIN INHIBITOR COMPOUNDS Pharmakea Inc. (US) 2016-07-27 EP disclosed
WO-2015042053-A1 VINYL AUTOTAXIN INHIBITOR COMPOUNDS PHARMAKEA, INC. (US) 2015-03-26 WO disclosed
WO-2009055002-A1 COMBINED INHIBITORS OF CYCLOOXYGENASE AND SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) (VASCULAR ADHESION PROTEIN, VAP-1) LA JOLLA PHARMACEUTICAL COMPANY (US) 2009-04-30 WO disclosed
WO-2009055002-A1 COMBINED INHIBITORS OF CYCLOOXYGENASE AND SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) (VASCULAR ADHESION PROTEIN, VAP-1) LA JOLLA PHARMACEUTICAL COMPANY (US) 2009-04-30 WO disclosed
EP-0874826-A1 NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION LABORATORIOS MENARINI S.A. (ES) 1998-11-04 EP disclosed
WO-1997024331-A1 NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION LABORATORIOS MENARINI S.A. (ES) 1997-07-10 WO disclosed
EP-0386839-B1 Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME (GB) 1997-01-15 EP disclosed
US-5231102-A Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME, LTD. (GB) 1993-07-27 US disclosed
EP-0386839-A2 Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME LTD. (GB) 1990-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222000-A1 VINYL AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, SERPINB1, SERPINB10 CA2 3036/4885CAMK2A 1823/4885AKR1B1 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.